Literature DB >> 2294640

Differential growth of human enteric adenovirus 41 (TAK) in continuous cell lines.

D Pieniazek1, N J Pieniazek, D Macejak, J Coward, M Rayfield, R B Luftig.   

Abstract

Differing reports exist about the replication of human enteric adenoviruses (EnAds) in various cell lines. There was a suggestion that EnAds are defective, do not grow on primary human diploid cells, and behave like Ad host-range mutants, i.e., they require early gene products from other Ad types for efficient growth. Thus, initially the Graham-293 cell line, which contains the E1 region (E1A, E1B) of Ad5, was thought to be an ideal host for EnAds, because it provided the needed functions. Our findings, however, question this contention and show that Ad41 strain TAK, cultured on 293 cells, rapidly loses its infectivity (greater than 90% on the first and 100% by the second passage). In contrast to the results with 293 cells, we found that Ad41 strain TAK can be serially grown to high titers on several continuous cell lines: namely, HeLa, HI407, or HEp-2 cells. In order to investigate the basis for the rapid loss of the Ad41 infectivity upon passaging in 293 cells, Ad41 virions were purified from 293, as well as from HEp-2 cells, and their composition was analyzed. When structural proteins of the complete virions (rho = 1.34 g/cm3) were compared by Western blot analysis using polyclonal antibodies to HEp-2-grown virus, only traces of protein V (Mr 46,000 Da) could be detected in particles from 293 cells. In contrast, Ad41 particles obtained from HEp-2 cells exhibited a strong band at the position of protein V. Further, if polyclonal antibodies to 293-grown Ad41 were used in the Western blot, no protein V band was detected in HEp-2-grown virus. Finally, we note that new protein bands (Mr 25,000-35,000 Da) could be observed upon Western blot analysis of 293-derived complete and incomplete Ad41 particles. All of these observations taken together suggest that the low infectivity of Ad41 particles, prepared from 293 cells, could be due to a defect in assembly.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294640     DOI: 10.1016/0042-6822(90)90072-y

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

2.  Genetic organization, size, and complete sequence of early region 3 genes of human adenovirus type 41.

Authors:  H Y Yeh; N Pieniazek; D Pieniazek; R B Luftig
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

3.  Adenovirus Infection of Human Enteroids Reveals Interferon Sensitivity and Preferential Infection of Goblet Cells.

Authors:  Mayumi K Holly; Jason G Smith
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

4.  Growth of fastidious adenovirus serotype 40 in HRT 18 cells: interactions with E1A and E1B deletion mutants of subgenus C adenoviruses.

Authors:  S A Gomes; C Niel; J C D'Halluin
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  A block in release of progeny virus and a high particle-to-infectious unit ratio contribute to poor growth of enteric adenovirus types 40 and 41 in cell culture.

Authors:  M Brown; H L Wilson-Friesen; F Doane
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  Adenovirus type 40 and 41 growth in vitro: host range diversity reflected by differences in patterns of DNA replication.

Authors:  C T Tiemessen; A H Kidd
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  Characterizations of adenovirus type 41 isolates from children with acute gastroenteritis in Japan, Vietnam, and Korea.

Authors:  Lei Li; Hideaki Shimizu; Lan Thi Phuong Doan; Phan Gia Tung; Shoko Okitsu; Osamu Nishio; Eiko Suzuki; Jeong Kee Seo; Kyo Sun Kim; Werner E G Müller; Hiroshi Ushijima
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.